Donald A Bergstrom
CIK 1709772 · President, R&D · last filed 2026-01-29
Donald A Bergstrom is a President, R&D who has filed 61 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing shows the insider sold $166.7K of RLAY on Jan 29, 2026. Across all open-market trades the lifetime net is −$10.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.26M
3
61
-$10.16M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RLAY | President, R&D | 422,733 | $14.81 | $6.26M | -$10.16M | 55 | 2026-01-29 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 5 | 2024-06-04 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | Chief Medical Officer | — | $29.08 | — | $0 | 1 | 2018-02-06 |
Recent Filings
61 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-29 | RLAY | Sell (S) | −21,581 | -$166.7K | EDGAR |
| 2026-01-15 | RLAY | Grant (A) | — | $0 | EDGAR |
| 2025-10-30 | RLAY | Sell (S) | −30,897 | -$225.2K | EDGAR |
| 2025-07-30 | RLAY | Sell (S) | −30,770 | -$113.5K | EDGAR |
| 2025-04-30 | RLAY | Sell (S) | −31,562 | -$95.4K | EDGAR |
| 2025-03-31 | RLAY | Sell (S) | −986 | -$2.8K | EDGAR |
| 2025-01-30 | RLAY | Mixed | +95,950 | -$362.3K | EDGAR |
| 2025-01-14 | RLAY | Grant (A) | — | $0 | EDGAR |
| 2024-12-31 | RLAY | Sell (S) | −657 | -$2.9K | EDGAR |
| 2024-10-30 | RLAY | Sell (S) | −2,688 | -$16.3K | EDGAR |